Is Europe the next frontier for healthtech investment?
Europe is a hotspot for innovation in healthtech. 40% of all IP developed for healthcare comes from Europe. Some of the world's top healthcare companies, universities, and academic hospitals can be found here. What's more, the non-dilutive environment for healthtech start-ups is very attractive, and as a result, a wide range of very promising companies are founded every year.
Get to know NLC, the European Healthtech Venture Builder.
Difference between US and EU
The European Valuation Gap
Despite all this, only 10% of all early-stage healthcare investments happen in Europe. That's because - besides being very innovative - Europe is also very fragmented. Smaller home markets and care system fragmentation make the road to scale longer. This also applies to other parts of the ecosystem, such as investors. As a result of this, the valuation for European healthtech companies is 3x lower than their US counterparts, despite the fact, their technologies are world-class.
Taking the advantage of significant opportunities
Crossing the Bridge
This makes for a very attractive arbitrage opportunity for investors in the healthtech space. Helping European ventures grow faster at home, and bringing them to Asia, the Middle East, Africa or the US can significantly reduce the time to scale, and as such, the valuation gap.
Even better, why invest in only one venture, if you can also invest in 100+ at once with NLC?
Start the conversation
Interested in investing?
NLC the European Healthtech Venture Builder has built over 100 start-ups across the continent. We collaborate with top companies like Philips, and top academic institutions such as Oxford and Charité, to build companies around their best IP, with 22 ventures founded in the year 2022 alone.
Come talk to us if you'd like to know more. Or send us your details and we'll get back to you.